Journal Publishes 36-Month CORE-VNS Results on LivaNova VNS Therapy
Neuromodulation: Technology at the Neural Interface published full 36-month results from the CORE-VNS study evaluating LivaNova’s VNS Therapy for drug-resistant epilepsy.
Story updates
01:01:02 PM UTC
SquawkNews
LivaNova published full 36-month CORE-VNS results showing a 76% median reduction in seizure frequency in DRE patients, with 64% achieving at least 50% reduction and no new safety concerns.Material DetailsContext by AI AnalystThis is late-stage confirmation of efficacy for LivaNova’s modern VNS in r…